Gustave Roussy Physicians Present Clinical Cancer Trials at ESMO 2026 Congress
Physicians and researchers from Gustave Roussy are presenting clinical trial findings spanning breast, lung, gastrointestinal, and paediatric cancers at the ...
Physicians and researchers from Gustave Roussy are presenting clinical trial findings spanning breast, lung, gastrointestinal, and paediatric cancers at the ...
New findings presented at the ESMO Congress 2026 cover ctDNA monitoring in lung and breast cancer, a re-vaccination strategy for ...
A Phase 3 trial found the next-generation KRAS G12C inhibitor divarasib extended median overall survival to 17.7 months versus 12 ...
A randomised phase III trial presented at ESMO 2026 shows that a hybrid care pathway combining a mobile application with ...
A Phase 1 trial presented at ESMO 2026 reports a 40% objective response rate at 130 mg for ISM6331, a ...
Phase 3 trial results presented at ESMO 2026 show that adding personalized mRNA vaccine intismeran to pembrolizumab reduces melanoma recurrence ...
Insilico Medicine plans to present first human Phase 1 data for the AI-designed pan-TEAD inhibitor ISM6331 in mesothelioma and other ...
Updated Phase 3 DUO-E trial results presented at ESMO 2026 show that durvalumab plus olaparib after chemotherapy achieved a median ...
A UCL analysis of the Decipher genomic test across real-world data and the STAMPEDE trial suggests the score can predict ...
Dana-Farber will present the phase 3 DeLLphi-305 primary analysis in extensive-stage small cell lung cancer at the 2026 ESMO Presidential ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine